With colorectal cancer on the rise in people under 50, researchers at the University of Illinois Urbana-Champaign are looking ...

With colorectal cancer on the rise in people under 50, researchers at the University of Illinois Urbana-Champaign are looking at the colon's tiniest ...

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...

Colorectal cancer cases are increasing among adults under 50, with screening guidelines now recommending starting at age 45.

Learn about toxic megacolon, a serious complication of IBD. Discover its causes, symptoms, diagnosis, treatment, and ...

Palisade Bio’s locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor, PALI-2108 receives Chinese patent: Carlsbad, California Monday, August 4, 2025, 16:00 Hrs ...

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical ...

With colorectal cancer ranking as the second leading cause of cancer-related deaths worldwide, the increasing reliance on colonoscopy for early detection and prevention is driving demand for ...